Immuneel Therapeutics
Bengaluru, India· Est.
India‑based biotech delivering low‑cost CAR‑T therapies for blood cancers.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
India‑based biotech delivering low‑cost CAR‑T therapies for blood cancers.
Oncology
Technology Platform
Autologous CAR‑T cell therapy platform that engineers patient T cells to target tumor antigens, with a focus on cost‑effective manufacturing for emerging markets.
Opportunities
Large unmet need for affordable CAR‑T therapies in India and potential to expand to other emerging markets as manufacturing scale improves.
Risk Factors
High capital requirements for GMP manufacturing, regulatory hurdles, and competition from established global CAR‑T players.
Competitive Landscape
Competes with global CAR‑T developers such as Novartis, Juno, and Kite, but differentiates through a low‑cost, India‑focused manufacturing model.